Featuring news, events and industry trends

Ascensia, Insulet Ink Diabetes Care Development Pact

Located in Valhalla, Ascensia Diabetes Care has signed a deal to connect its blood glucose monitoring system to Insulet’s in-development tubeless insulin delivery system. The combined system will measure a patient’s glucose levels, then calculate and deliver the right insulin dose.

Under the agreement, Insulet will pursue FDA clearance for its Omnipod Dash personal diabetes manager in collaboration with Ascensia, which will bring its Contour Next One glucose meter and test strips to the table.

The Contour system will transmit a patient’s blood glucose data via Bluetooth to the Omnipod Dash, which will use those readings to calculate and deliver the appropriate insulin dose, according to a statement. The Dash is based on the company’s Omnipod insulin delivery system.

Retia Medical Secures 510(k) Green Light for its Less-Invasive Cardiac Output Monitor

The FDA granted a 510(k) clearance to Retia Medical’s hemodynamic monitoring device for measuring a patient’s cardiac output in intensive care units or the operating room.

The Valhalla, New York-based company’s Argos monitor uses “multibeat analysis” algorithms and signal processing, which employ a blood pressure waveform derived from up to 20 heartbeats to produce a model of an adult patient’s circulation.

Retia says the monitor will help provide clinicians with accurate data to help track oxygen delivery and maintain the optimal fluid status in high-risk surgical and critically ill patients. In addition, the system integrates with current vital sign monitors and common electronic medical records platforms.

Regeneron, BARDA Partner to Develop MERS Virus Treatment

Tarrytown headquartered Regeneron Pharmaceuticals and the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) have done a deal to develop a pair of antibodies to prevent and treat Middle East Respiratory Syndrome (MERS). These MERS antibodies were discovered and developed under Regeneron’s deal with Sanofi--and are subject to opt-in rights from Sanofi.

The pair, Regeneron and BARDA, already have an existing agreement for an Ebola therapy that was discovered by Regeneron and has recently entered Phase I testing, as well as received an Orphan Drug Designation from the FDA. The company uses its VelociGene and VelocImmune technologies for the identification and preclinical validation of antibodies.

Clinical Trial: Rehabilitation After Nerve Transfer to Treat Cervical Spinal Cord Injury

White Plains-headquartered, Burke Neurological Institute is conducting research to determine how rehabilitation therapy can improve arm function after nerve transfer surgery to treat spinal cord injury. Nerve transfer surgery is often an outpatient procedure that involves cutting branches of one nerve and suturing them to another.


Participants are being actively recruited for this trial with the following inclusion criteria: 

·       18-65 years old

·       Both (Male and Female)

·       Had a cervical spinal cord injury at least 6 months ago

·       Experience residual hand weakness


For more information, please contact Amanda Bernstein amb3005@med.cornell.edu or (914) 597-2111.


Westchester County Biosciences Accelerator (WCBA) 2022-2023 Program Schedule

WCBA is the first and only competitive-entry, six-month program of personalized entrepreneurial education delivered for first time founders of bioscience ventures of any development stage focused on healthcare innovation in Westchester. WCBA focuses on unlocking the unknown by addressing individual needs and utilizing accredited entrepreneur coaches and expert mentors to craft unique, educational experiences crucial to the development of successful ventures.

The complete education and support program can be found here.


NewYorkBio Annual Meeting

“Vision" talks with speakers who will inspire, drive our idea of what's possible and make us think about the heights that science and innovation can achieve for human health are back for 2022.

Date: September 28


Clinical Trials Master Class: Diversity, Equity, & Inclusion

Clinical trials are evolving following COVID vaccine approvals. If you are planning your first clinical trial or seek best practices to achieve health equity join us at the expert-led Master Class from ELabNYC.  

Network with speakers at a pre-event reception at Moses & Singer’s Chrysler Building office and attend the Master Class sessions online. Virtual networking supported during and after the event.  

Date: October 12-October 14


Have good news to share from
Westchester’s bioscience ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.

Facebook  Twitter  Instagram  Linkedin